Herbert Y. Meltzer

Herbert Y. Meltzer is an American scientist and professor of psychiatry and behavioral sciences, pharmacology and physiology and director of the Translational Neuropharmacology Program at Northwestern University, best known for his research on the treatment of schizophrenia. [1] He is the author of over 1,000 publications.[2]

Education

Herbert received his bachelor's degree from Cornell University, a master's in chemistry from Harvard University, and his MD from Yale University.[3]

Research career

During his research career, Meltzer discovered the effectiveness of clozapine in treating suicide attempts in patients with schizophrenia, which led to FDA approval of clozapine for treating suicide.[4][5][6] He also discovered that clozapine can improve cognition.[7]

Meltzer also worked on the research on pimavanserin which targets serotonin 5-HT2A receptor and is effective in treating psychosis in Parkinson's disease.[8]

Herbert Y. Meltzer is currently leading the active clinical trial for JNJ-18038683.

References

1. "When Will Mental Illness Finally Yield to Science?". Newsweek. 11 August 2014. Retrieved 2022-02-20.
2. "Meltzer Honored for Contributions to Psychopharmacology". NorthwesternMedicine. 10 June 2016. Retrieved 2022-02-18.
3. "Herbert Y Meltzer, MD". Feinburg School of Medicine. Retrieved 7 April 2022.
4. Meltzer, H; Alphs, L; Green, A; Altamura, A; Anand, R; Bertoldi, A (2003). "Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)". Arch Gen Psychiatry. 60 (1): 82–91. doi:10.1001/archpsyc.60.1.82. PMID 12511175. S2CID 15444200.
5. "Pioneer in Clozapine Research Wins Major Psychopharmacology Award". PsychNews. 15 July 2016. doi:10.1176/appi.pn.2016.PP7a2 (inactive 1 November 2024). Retrieved 2022-02-18.
6. "Four Decades Later, Meltzer's Work on Schizophrenia Still Breaking New Ground". NorthwesternMedicine. 21 May 2013. Retrieved 2022-02-19.
7. "Psychopharmacologic Innovations in the Treatment of Schizophrenia, Past and Present: An Expert Interview With Herbert Y. Meltzer". Medscape. Retrieved 2022-02-10.
8. Meltzer, H; Mills, R; Revell, S; Williams, H; Johnson, A; Bahr, D; Friedman, J (2010). "Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis". Neuropsychopharmacology. 35 (4): 881–92. doi:10.1038/npp.2009.176. PMC 3055369. PMID 19907417.